Course of B-cell total population and subpopulations in HCV-MC patients according to the type of treatment. (A) CD19⁺ B cells. (B) Naive B cells. (C) Memory B cells. (D) B-cell depletion after rituximab plus Peg-IFN-α/ribavirin. (E) Analysis of B-cell subpopulations after rituximab plus Peg-IFN-α/ribavirin. RTX indicates rituximab; and RBV, ribavirin.